Header Logo

Connection

Cynthia Comella to Humans

Back to Details
This is a "connection" page, showing publications Cynthia Comella has written about Humans.
Cynthia Comella
Connection Strength
1.695
Humans
  1. On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med. 2021 Sep; 133(7):721-727.
    View in: PubMed
    Score: 0.041
  2. Patient perspectives on the therapeutic profile of botulinum neurotoxin type A in cervical dystonia. J Neurol. 2021 Mar; 268(3):903-912.
    View in: PubMed
    Score: 0.039
  3. Recent developments in drug-induced movement disorders: a mixed picture. Lancet Neurol. 2019 09; 18(9):880-890.
    View in: PubMed
    Score: 0.036
  4. Reliability, feasibility and satisfaction of telemedicine evaluations for cervical dystonia. J Telemed Telecare. 2020 Oct; 26(9):560-567.
    View in: PubMed
    Score: 0.036
  5. Valbenazine in the treatment of tardive dyskinesia. Neurodegener Dis Manag. 2019 04; 9(2):73-81.
    View in: PubMed
    Score: 0.035
  6. Progressive Encephalomyelitis With Rigidity and Myoclonus Syndrome Presenting as Catatonia. Psychosomatics. 2019 Jan - Feb; 60(1):83-87.
    View in: PubMed
    Score: 0.033
  7. Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale. Parkinsonism Relat Disord. 2018 07; 52:94-97.
    View in: PubMed
    Score: 0.033
  8. Systematic review of botulinum toxin treatment for oromandibular dystonia. Toxicon. 2018 Jun 01; 147:96-99.
    View in: PubMed
    Score: 0.032
  9. Dystonia: Then and now. Parkinsonism Relat Disord. 2018 Jan; 46 Suppl 1:S66-S69.
    View in: PubMed
    Score: 0.031
  10. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry. J Neurol Sci. 2017 May 15; 376:84-90.
    View in: PubMed
    Score: 0.030
  11. Clinimetric testing of the comprehensive cervical dystonia rating scale. Mov Disord. 2016 Apr; 31(4):563-9.
    View in: PubMed
    Score: 0.028
  12. Botulinum Toxin Treatment of Cervical Dystonia. Semin Neurol. 2016 Feb; 36(1):47-53.
    View in: PubMed
    Score: 0.028
  13. Therapeutic advances in restless legs syndrome (RLS). Mov Disord. 2015 Sep 15; 30(11):1574-9.
    View in: PubMed
    Score: 0.027
  14. Clinical and pharmacological properties of incobotulinumtoxinA and its use in neurological disorders. Drug Des Devel Ther. 2015; 9:1913-26.
    View in: PubMed
    Score: 0.027
  15. When brawn benefits brain: physical activity and Parkinson's disease risk. Brain. 2015 Feb; 138(Pt 2):238-9.
    View in: PubMed
    Score: 0.026
  16. An international survey of patients with cervical dystonia. J Neurol. 2015; 262(4):837-48.
    View in: PubMed
    Score: 0.026
  17. Beyond a motor disorder: a prospective evaluation of sleep quality in cervical dystonia. Parkinsonism Relat Disord. 2014 Apr; 20(4):405-8.
    View in: PubMed
    Score: 0.024
  18. Treatment of restless legs syndrome. Neurotherapeutics. 2014 Jan; 11(1):177-87.
    View in: PubMed
    Score: 0.024
  19. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(?)) in cervical dystonia. J Neural Transm (Vienna). 2013 Dec; 120(12):1699-707.
    View in: PubMed
    Score: 0.023
  20. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 2013 Aug; 28(9):1230-40.
    View in: PubMed
    Score: 0.023
  21. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN?, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15; 308(1-2):103-9.
    View in: PubMed
    Score: 0.021
  22. Dystonias of the head and neck: An overview. Ear Nose Throat J. 2011 Feb; 90(2):E4.
    View in: PubMed
    Score: 0.020
  23. Sleep disorders in Parkinson's disease. Handb Clin Neurol. 2011; 99:997-1010.
    View in: PubMed
    Score: 0.020
  24. Early-onset primary dystonia. Handb Clin Neurol. 2011; 100:465-79.
    View in: PubMed
    Score: 0.020
  25. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009 Oct; 54(5):628-33.
    View in: PubMed
    Score: 0.017
  26. The treatment of cervical dystonia with botulinum toxins. J Neural Transm (Vienna). 2008; 115(4):579-83.
    View in: PubMed
    Score: 0.016
  27. Sleep disorders in Parkinson's disease: an overview. Mov Disord. 2007 Sep; 22 Suppl 17:S367-73.
    View in: PubMed
    Score: 0.016
  28. Treatment of cervical dystonia with botulinum toxins. Eur J Neurol. 2006 Feb; 13 Suppl 1:16-20.
    View in: PubMed
    Score: 0.014
  29. Can families be screened for cervical dystonia using a telephone interview? Nat Clin Pract Neurol. 2006 Jan; 2(1):20-1.
    View in: PubMed
    Score: 0.014
  30. Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview. J Neural Transm Suppl. 2006; (70):349-55.
    View in: PubMed
    Score: 0.014
  31. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005 Nov 08; 65(9):1423-9.
    View in: PubMed
    Score: 0.014
  32. Restless legs syndrome. Prim Care. 2005 Jun; 32(2):435-48.
    View in: PubMed
    Score: 0.013
  33. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology. 2005 Apr 26; 64(8):1450-1.
    View in: PubMed
    Score: 0.013
  34. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. Mov Disord. 2005; 20 Suppl 11:S30-7.
    View in: PubMed
    Score: 0.013
  35. Botulinum toxins in neurological disease. Muscle Nerve. 2004 May; 29(5):628-44.
    View in: PubMed
    Score: 0.012
  36. The effect of botulinum toxin on anxiety in cervical dystonia: A prospective, observational study. Parkinsonism Relat Disord. 2023 09; 114:105792.
    View in: PubMed
    Score: 0.012
  37. Sleep episodes in Parkinson's disease: more questions remain. Sleep Med. 2003 Jul; 4(4):267-8.
    View in: PubMed
    Score: 0.012
  38. Social Skills and Cognitive Training to Support Work-Related Skills and Job Placement in a Group of Autistic Adults : Effectiveness of a Neuropsychological and Social Skills Intervention: A Case Series Study on a Pilot Program. Community Ment Health J. 2023 11; 59(8):1610-1618.
    View in: PubMed
    Score: 0.012
  39. Isolated Cervical Dystonia: Diagnosis and Classification. Mov Disord. 2023 08; 38(8):1367-1378.
    View in: PubMed
    Score: 0.012
  40. Sleep disturbances in Parkinson's disease. Curr Neurol Neurosci Rep. 2003 Mar; 3(2):173-80.
    View in: PubMed
    Score: 0.011
  41. Rating scales for dystonia: a multicenter assessment. Mov Disord. 2003 Mar; 18(3):303-312.
    View in: PubMed
    Score: 0.011
  42. Treatment of dystonia. Clin Neuropharmacol. 2003 Mar-Apr; 26(2):102-8.
    View in: PubMed
    Score: 0.011
  43. Validation of a guideline to reduce variability in diagnosing cervical dystonia. J Neurol. 2023 May; 270(5):2606-2612.
    View in: PubMed
    Score: 0.011
  44. Determinants of gait dystonia severity in cerebral palsy. Dev Med Child Neurol. 2023 07; 65(7):968-977.
    View in: PubMed
    Score: 0.011
  45. Motor and psychiatric features in idiopathic blepharospasm: A data-driven cluster analysis. Parkinsonism Relat Disord. 2022 Nov; 104:94-98.
    View in: PubMed
    Score: 0.011
  46. Advanced diffusion imaging to track progression in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neuroimage Clin. 2022; 34:103022.
    View in: PubMed
    Score: 0.011
  47. Hold that pose: capturing cervical dystonia's head deviation severity from video. Ann Clin Transl Neurol. 2022 05; 9(5):684-694.
    View in: PubMed
    Score: 0.011
  48. Restless legs syndrome: treatment with dopaminergic agents. Neurology. 2002 Feb 26; 58(4 Suppl 1):S87-92.
    View in: PubMed
    Score: 0.011
  49. Head tremor in cervical dystonia: Quantifying severity with computer vision. J Neurol Sci. 2022 Mar 15; 434:120154.
    View in: PubMed
    Score: 0.011
  50. Daytime sleepiness, agonist therapy, and driving in Parkinson disease. JAMA. 2002 Jan 23-30; 287(4):509-11.
    View in: PubMed
    Score: 0.011
  51. Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. Neurology. 2001 Oct 23; 57(8):1519.
    View in: PubMed
    Score: 0.010
  52. Diagnostic criteria for blepharospasm: A multicenter international study. Parkinsonism Relat Disord. 2021 10; 91:109-114.
    View in: PubMed
    Score: 0.010
  53. Non-motor phenotypic subgroups in adult-onset idiopathic, isolated, focal cervical dystonia. Brain Behav. 2021 08; 11(8):e2292.
    View in: PubMed
    Score: 0.010
  54. Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial. Mov Disord. 2021 10; 36(10):2408-2412.
    View in: PubMed
    Score: 0.010
  55. Does Raising the Arms Modify Head Tremor Severity in Cervical Dystonia? Tremor Other Hyperkinet Mov (N Y). 2021 06 23; 11:21.
    View in: PubMed
    Score: 0.010
  56. Head tremor and pain in cervical dystonia. J Neurol. 2021 May; 268(5):1945-1950.
    View in: PubMed
    Score: 0.010
  57. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice. CNS Spectr. 2022 04; 27(2):208-217.
    View in: PubMed
    Score: 0.010
  58. Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration. Mov Disord. 2021 06; 36(6):1342-1352.
    View in: PubMed
    Score: 0.010
  59. It's tricky: Rating alleviating maneuvers in cervical dystonia. J Neurol Sci. 2020 Dec 15; 419:117205.
    View in: PubMed
    Score: 0.010
  60. Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. Neurology. 2021 01 26; 96(4):e563-e574.
    View in: PubMed
    Score: 0.010
  61. KICK OUT PD: Feasibility and quality of life in the pilot karate intervention to change kinematic outcomes in Parkinson's Disease. PLoS One. 2020; 15(9):e0237777.
    View in: PubMed
    Score: 0.010
  62. Postural Directionality and Head Tremor in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2020; 10.
    View in: PubMed
    Score: 0.009
  63. Use of botulinum toxin type A in the treatment of cervical dystonia. Neurology. 2000; 55(12 Suppl 5):S15-21.
    View in: PubMed
    Score: 0.009
  64. Cervical dystonia incidence and diagnostic delay in a multiethnic population. Mov Disord. 2020 03; 35(3):450-456.
    View in: PubMed
    Score: 0.009
  65. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. J Clin Psychopharmacol. 2019 Nov/Dec; 39(6):620-627.
    View in: PubMed
    Score: 0.009
  66. Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.009
  67. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.009
  68. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp. 2019 12 01; 40(17):5094-5107.
    View in: PubMed
    Score: 0.009
  69. Sensory Tricks Are Associated with Higher Sleep-Related Quality of Life in Cervical Dystonia. Tremor Other Hyperkinet Mov (N Y). 2019; 9.
    View in: PubMed
    Score: 0.009
  70. Head tremor at disease onset: an ataxic phenotype of cervical dystonia. J Neurol. 2019 Aug; 266(8):1844-1851.
    View in: PubMed
    Score: 0.009
  71. Recruitment of patients with de novo Parkinson disease: successful strategies in a randomized exercise clinical trial. Trials. 2018 Nov 14; 19(1):630.
    View in: PubMed
    Score: 0.009
  72. Predictors of alcohol responsiveness in dystonia. Neurology. 2018 11 20; 91(21):e2020-e2026.
    View in: PubMed
    Score: 0.008
  73. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998 Aug; 51(2):526-9.
    View in: PubMed
    Score: 0.008
  74. Extensor truncal dystonia: successful treatment with botulinum toxin injections. Mov Disord. 1998 May; 13(3):552-5.
    View in: PubMed
    Score: 0.008
  75. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.008
  76. Effect of High-Intensity Treadmill Exercise on Motor Symptoms in Patients With De Novo Parkinson Disease: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2018 02 01; 75(2):219-226.
    View in: PubMed
    Score: 0.008
  77. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017 Nov/Dec; 78(9):1344-1350.
    View in: PubMed
    Score: 0.008
  78. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy? Toxicon. 2018 Jun 01; 147:89-95.
    View in: PubMed
    Score: 0.008
  79. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord. 1997 Jul; 12(4):570-5.
    View in: PubMed
    Score: 0.008
  80. Factors Associated With Ambulatory Activity in De Novo Parkinson Disease. J Neurol Phys Ther. 2017 Apr; 41(2):93-100.
    View in: PubMed
    Score: 0.008
  81. Effects of 2 Years of Exercise on Gait Impairment in People With Parkinson Disease: The PRET-PD Randomized Trial. J Neurol Phys Ther. 2017 Jan; 41(1):21-30.
    View in: PubMed
    Score: 0.007
  82. The best medicine? The influence of physical activity and inactivity on Parkinson's disease. Mov Disord. 2016 10; 31(10):1444-1454.
    View in: PubMed
    Score: 0.007
  83. Progressive resistance exercise restores some properties of the triphasic EMG pattern and improves bradykinesia: the PRET-PD randomized clinical trial. J Neurophysiol. 2016 11 01; 116(5):2298-2311.
    View in: PubMed
    Score: 0.007
  84. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 May 10; 86(19):1818-26.
    View in: PubMed
    Score: 0.007
  85. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. JAMA Neurol. 2016 Jan; 73(1):102-10.
    View in: PubMed
    Score: 0.007
  86. Exercise improves cognition in Parkinson's disease: The PRET-PD randomized, clinical trial. Mov Disord. 2015 Oct; 30(12):1657-63.
    View in: PubMed
    Score: 0.007
  87. Secured web-based video repository for multicenter studies. Parkinsonism Relat Disord. 2015 Apr; 21(4):366-71.
    View in: PubMed
    Score: 0.007
  88. Effects of endurance exercise training on the motor and non-motor features of Parkinson's disease: a review. J Parkinsons Dis. 2015; 5(1):21-41.
    View in: PubMed
    Score: 0.007
  89. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE). J Neurol Sci. 2015 Feb 15; 349(1-2):84-93.
    View in: PubMed
    Score: 0.007
  90. Distinct functional and macrostructural brain changes in Parkinson's disease and multiple system atrophy. Hum Brain Mapp. 2015 Mar; 36(3):1165-79.
    View in: PubMed
    Score: 0.006
  91. The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD study. Mov Disord. 2015 Feb; 30(2):278-83.
    View in: PubMed
    Score: 0.006
  92. Akathisia in Parkinson's disease. Mov Disord. 1994 Sep; 9(5):545-9.
    View in: PubMed
    Score: 0.006
  93. IncobotulinumtoxinA (Xeomin?) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated. J Neurol Sci. 2014 Nov 15; 346(1-2):116-20.
    View in: PubMed
    Score: 0.006
  94. Subthalamic nucleus--sensorimotor cortex functional connectivity in de novo and moderate Parkinson's disease. Neurobiol Aging. 2015 Jan; 36(1):462-9.
    View in: PubMed
    Score: 0.006
  95. Two-year exercise program improves physical function in Parkinson's disease: the PRET-PD randomized clinical trial. Neurorehabil Neural Repair. 2015 Feb; 29(2):112-22.
    View in: PubMed
    Score: 0.006
  96. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy). J Neurol. 2014 Jul; 261(7):1309-19.
    View in: PubMed
    Score: 0.006
  97. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology. 1994 Mar; 44(3 Pt 1):376-8.
    View in: PubMed
    Score: 0.006
  98. Cognitive and motor function in long-duration PARKIN-associated Parkinson disease. JAMA Neurol. 2014 Jan; 71(1):62-7.
    View in: PubMed
    Score: 0.006
  99. Designing clinical trials for dystonia. Neurotherapeutics. 2014 Jan; 11(1):117-27.
    View in: PubMed
    Score: 0.006
  100. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol. 1993 Nov; 34(5):710-4.
    View in: PubMed
    Score: 0.006
  101. Diffusion, spread, and migration of botulinum toxin. Mov Disord. 2013 Nov; 28(13):1775-83.
    View in: PubMed
    Score: 0.006
  102. Dystonia rating scales: critique and recommendations. Mov Disord. 2013 Jun 15; 28(7):874-83.
    View in: PubMed
    Score: 0.006
  103. The focal dystonias: current views and challenges for future research. Mov Disord. 2013 Jun 15; 28(7):926-43.
    View in: PubMed
    Score: 0.006
  104. Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol. 2013 Aug; 12(8):747-55.
    View in: PubMed
    Score: 0.006
  105. Diffusion tensor imaging of Parkinson's disease, atypical parkinsonism, and essential tremor. Mov Disord. 2013 Nov; 28(13):1816-22.
    View in: PubMed
    Score: 0.006
  106. Force control deficits in individuals with Parkinson's disease, multiple systems atrophy, and progressive supranuclear palsy. PLoS One. 2013; 8(3):e58403.
    View in: PubMed
    Score: 0.006
  107. Differences in brain activation between tremor- and nontremor-dominant Parkinson disease. JAMA Neurol. 2013 Jan; 70(1):100-6.
    View in: PubMed
    Score: 0.006
  108. Reliability of a new scale for essential tremor. Mov Disord. 2012 Oct; 27(12):1567-9.
    View in: PubMed
    Score: 0.006
  109. Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiologic findings. Neurology. 1992 Jul; 42(7):1307-10.
    View in: PubMed
    Score: 0.005
  110. Tai chi for patients with Parkinson's disease. N Engl J Med. 2012 05 03; 366(18):1737-8; author reply 1738.
    View in: PubMed
    Score: 0.005
  111. Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology. 1992 Apr; 42(4):878-82.
    View in: PubMed
    Score: 0.005
  112. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012 May 01; 78(18):1434-40.
    View in: PubMed
    Score: 0.005
  113. The relation between depression and parkin genotype: the CORE-PD study. Parkinsonism Relat Disord. 2011 Dec; 17(10):740-4.
    View in: PubMed
    Score: 0.005
  114. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE). BMC Neurol. 2011 Nov 04; 11:140.
    View in: PubMed
    Score: 0.005
  115. Pre-operative evaluations for DBS in dystonia. Mov Disord. 2011 Jun; 26 Suppl 1:S17-22.
    View in: PubMed
    Score: 0.005
  116. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011 Jul; 26(8):1521-8.
    View in: PubMed
    Score: 0.005
  117. Jaw-opening dystonia: Quality of life after botulinum toxin injections. Ear Nose Throat J. 2011 Feb; 90(2):E9.
    View in: PubMed
    Score: 0.005
  118. Olfaction in Parkin heterozygotes and compound heterozygotes: the CORE-PD study. Neurology. 2011 Jan 25; 76(4):319-26.
    View in: PubMed
    Score: 0.005
  119. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord. 2010 Dec 15; 25(16):2704-16.
    View in: PubMed
    Score: 0.005
  120. Neuropsychological Profile of Parkin Mutation Carriers with and without Parkinson Disease: The CORE-PD Study. J Int Neuropsychol Soc. 2011 Jan; 17(1):91-100.
    View in: PubMed
    Score: 0.005
  121. Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease. Mov Disord. 2010 Oct 15; 25(13):2035-43.
    View in: PubMed
    Score: 0.005
  122. New approaches in the treatment of the dystonias. Klin Wochenschr. 1990 Oct 03; 68(19):935-41.
    View in: PubMed
    Score: 0.005
  123. Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. Arch Neurol. 2010 Sep; 67(9):1116-22.
    View in: PubMed
    Score: 0.005
  124. Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study. Mov Disord. 2010 Aug 15; 25(11):1627-32.
    View in: PubMed
    Score: 0.005
  125. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Mov Disord. 2010 Aug 15; 25(11):1708-14.
    View in: PubMed
    Score: 0.005
  126. Predictors of parkin mutations in early-onset Parkinson disease: the consortium on risk for early-onset Parkinson disease study. Arch Neurol. 2010 Jun; 67(6):731-8.
    View in: PubMed
    Score: 0.005
  127. Basal ganglia hypoactivity during grip force in drug na?ve Parkinson's disease. Hum Brain Mapp. 2010 Dec; 31(12):1928-41.
    View in: PubMed
    Score: 0.005
  128. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset Parkinson's disease. J Clin Exp Neuropsychol. 2010 Aug; 32(7):775-9.
    View in: PubMed
    Score: 0.005
  129. Motor phenotype of LRRK2 G2019S carriers in early-onset Parkinson disease. Arch Neurol. 2009 Dec; 66(12):1517-22.
    View in: PubMed
    Score: 0.005
  130. Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia. J Neurosurg. 2009 Feb; 110(2):229-33.
    View in: PubMed
    Score: 0.004
  131. Treatment of early Parkinson's disease. Part 1. Eur Neurol. 2009; 61(4):193-205.
    View in: PubMed
    Score: 0.004
  132. Treatment of early Parkinson's disease. Part 2. Eur Neurol. 2009; 61(4):206-15.
    View in: PubMed
    Score: 0.004
  133. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology. 2009 Apr 21; 72(16):1378-84.
    View in: PubMed
    Score: 0.004
  134. Variability of EMG patterns: a potential neurophysiological marker of Parkinson's disease? Clin Neurophysiol. 2009 Feb; 120(2):390-7.
    View in: PubMed
    Score: 0.004
  135. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology. 2008 Aug 12; 71(7):481-5.
    View in: PubMed
    Score: 0.004
  136. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008 Jul 30; 23(10):1353-60.
    View in: PubMed
    Score: 0.004
  137. Changes in the relationship between movement velocity and movement distance in primary focal hand dystonia. J Mot Behav. 2008 Jul; 40(4):301-13.
    View in: PubMed
    Score: 0.004
  138. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 May 06; 70(19):1699-706.
    View in: PubMed
    Score: 0.004
  139. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008; 14(5):407-14.
    View in: PubMed
    Score: 0.004
  140. Parkinson's disease--Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Manag Care. 2008 Mar; 14(2 Suppl):S40-8.
    View in: PubMed
    Score: 0.004
  141. Parkinson's disease--Part 2: Treatment of motor symptoms. Am J Manag Care. 2008 Mar; 14(2 Suppl):S49-58.
    View in: PubMed
    Score: 0.004
  142. Parkinson's disease--Part 3: Neuropsychiatric symptoms. Am J Manag Care. 2008 Mar; 14(2 Suppl):S59-69.
    View in: PubMed
    Score: 0.004
  143. Fatigue in Parkinson's disease: a review. Mov Disord. 2007 Feb 15; 22(3):297-308.
    View in: PubMed
    Score: 0.004
  144. Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system. Mov Disord. 2007; 22 Suppl 18:S424-30.
    View in: PubMed
    Score: 0.004
  145. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology. 2006 Dec 26; 67(12):2233-5.
    View in: PubMed
    Score: 0.004
  146. Association of daytime napping and Parkinsonian signs in Alzheimer's disease. Sleep Med. 2006 Dec; 7(8):614-8.
    View in: PubMed
    Score: 0.004
  147. Rate of force production and relaxation is impaired in patients with focal hand dystonia. Parkinsonism Relat Disord. 2006 Sep; 12(6):363-71.
    View in: PubMed
    Score: 0.004
  148. Strength deficits in primary focal hand dystonia. Mov Disord. 2006 Jan; 21(1):18-27.
    View in: PubMed
    Score: 0.003
  149. Rating scale for psychogenic movement disorders: scale development and clinimetric testing. Mov Disord. 2005 Dec; 20(12):1592-7.
    View in: PubMed
    Score: 0.003
  150. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul; 20(7):783-91.
    View in: PubMed
    Score: 0.003
  151. Force control and disease severity in Parkinson's disease. Mov Disord. 2005 Apr; 20(4):441-450.
    View in: PubMed
    Score: 0.003
  152. Muscle activation patterns in point-to-point and reversal movements in healthy, older subjects and in subjects with Parkinson's disease. Exp Brain Res. 2004 Jul; 157(1):67-78.
    View in: PubMed
    Score: 0.003
  153. Greater impairment of extension movements as compared to flexion movements in Parkinson's disease. Exp Brain Res. 2004 May; 156(2):240-54.
    View in: PubMed
    Score: 0.003
  154. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61.
    View in: PubMed
    Score: 0.003
  155. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology. 2003 Jan 14; 60(1):69-73.
    View in: PubMed
    Score: 0.003
  156. Benefits and risks of pharmacological treatments for essential tremor. Drug Saf. 2003; 26(7):461-81.
    View in: PubMed
    Score: 0.003
  157. Effect of medication on EMG patterns in individuals with Parkinson's disease. Mov Disord. 2002 Sep; 17(5):950-60.
    View in: PubMed
    Score: 0.003
  158. Control of movement distance in Parkinson's disease. Mov Disord. 2001 Nov; 16(6):1048-65.
    View in: PubMed
    Score: 0.003
  159. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001 Jun 12; 56(11):1523-8.
    View in: PubMed
    Score: 0.003
  160. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology. 2001 Feb 27; 56(4):455-62.
    View in: PubMed
    Score: 0.002
  161. A teaching videotape for the assessment of essential tremor. Mov Disord. 2001 Jan; 16(1):89-93.
    View in: PubMed
    Score: 0.002
  162. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology. 2000 Nov 28; 55(10):1572-5.
    View in: PubMed
    Score: 0.002
  163. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999 Oct 22; 53(7):1431-8.
    View in: PubMed
    Score: 0.002
  164. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999 Oct 22; 53(7):1439-46.
    View in: PubMed
    Score: 0.002
  165. The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). Mov Disord. 1998 May; 13(3):490-6.
    View in: PubMed
    Score: 0.002
  166. Sustained effect of high-dose intrathecal baclofen in primary generalized dystonia: a 2-year follow-up study. Mov Disord. 1997 Nov; 12(6):1100-2.
    View in: PubMed
    Score: 0.002
  167. [Botulin toxin: principles of action and neurological indications]. Presse Med. 1997 Feb 01; 26(2):96-100.
    View in: PubMed
    Score: 0.002
  168. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol. 1993 Jun; 16(3):205-10.
    View in: PubMed
    Score: 0.001
  169. Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology. 1990 Feb; 40(2):273-6.
    View in: PubMed
    Score: 0.001
  170. The adrenal medullary transplant operation for Parkinson's disease: clinical observations in five patients. Neurosurgery. 1988 Jun; 22(6 Pt 1):999-1004.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.